Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAfety of Mesenchymal Stromal Cells for Ischemic Stroke
NCT01922908Phase 2Withdrawn
- Start
- Dec 2016
- Primary completion
- Dec 2018
- Modality
- Stem Cell Therapies
01
Overview
A Phase 2 trial of allogeneic bone marrow-derived mesenchymal stem cells in ischemic stroke. Planned start Dec 2016; status: withdrawn.
02
Drugs
allogeneic bone marrow-derived mesenchymal stem cells
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT01922908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01922908.